Dell falls as soft current quarter guide offsets Q2 beat, full-year outlook lift
Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) stock gained 2.9% after the company announced that its collaborator RemeGen Co., Ltd (HKEX:9995, SHA:688331) achieved the primary endpoint in Stage A of a Phase 3 clinical study for telitacicept in adults with IgA nephropathy (IgAN).
The China-based study demonstrated a significant 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at 39 weeks compared to placebo (p<0.0001). The trial enrolled 318 adult IgAN patients who had received standard therapy.
"Telitacicept continues to demonstrate consistent, disease-modifying activity across autoimmune conditions, from myasthenia gravis to Sjögren’s disease and now IgA nephropathy," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board at Vor Bio.
Following these positive results, RemeGen plans to submit a Biologics License Application to China’s National Medical Products Administration. If approved, IgAN would become telitacicept’s fifth approved indication in China.
The clinical-stage biotechnology company noted that detailed study results will be presented at an upcoming medical conference. Vor Bio is focused on transforming the treatment of autoimmune diseases through its collaboration with RemeGen.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.